IP Library Granted Patent US 12678443
Granted Patent B2
US 12678443 · App. 18/655,985 · Granted Jul 14, 2026

Medicament for preventing and/or treating dry eye

Inventors: Kenji Oki (Minoh, JP); Takashi Nagano (Osaka, JP); Nagayoshi Asano (Ikoma, JP); Koushi Fujisawa (Ikoma, JP)
Assignees: SANTEN PHARMACEUTICAL CO., LTD.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH
A61K31/536A61K31/538A61P27/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678443
App. No.
18/655,985
Granted
Jul 14, 2026
Kind
B2
Abstract

A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. A method of preventing and/or treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol or a salt thereof to the subject is also provided.

Claims (10)

1 . A method of stabilizing tear film in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol hydrochloride to the subject.

2 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.1% (w/v) or less.

3 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.01% (w/v) or less.

4 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.1% (w/v).

5 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.01% (w/v).

6 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.005% (w/v).

7 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.00001 to 0.001% (w/v).

8 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in a concentration of 0.0001 to 0.001% (w/v).

9 . The method according to claim 1 , wherein the olodaterol hydrochloride is administered in the form of an eye drop.

10 . The method according to claim 1 , wherein administering the olodaterol hydrochloride does not substantially increase and/or reduce intraocular pressure.